A doctor is using Lunit INSIGHT MMG diagnosis software in this photo provided by Lunit.
SEOUL, June 23 (Korea Bizwire) — Medical artificial intelligence (AI) companies are making great strides with the scope of their services being diversified from the diagnosis of hard-to-diagnose diseases to the prediction of the risk of being afflicted with specific diseases.
South Korean startup VUNO Inc. published the world’s first cardiac arrest-related paper in the Critical Care Medicine journal. This paper is based on clinical data from the Mediflex Sejong Hospital.
VUNO’s related product ‘VUNO Med-Deep CARS’ is now able to predict the risk of cardiac arrest in 30 minutes at the earliest or less than 24 hours at the latest before cardiac arrest occurs.
JLK Inc., the first company listed among the nation’s medical AI firms, geared up for the expansion of its business after its AI-based prostate cancer diagnosis software acquired approval from the Ministry of Food and Drug Safety in April.
JLK strengthened the function of classifying and identifying lesions through deep learning-based data standardization.
It not only automatically analyzes the position of the cancer in the image but also delivers the probability value of cancer in a visual format.
The primary factor behind the prominence of medical AI firms is the easing of patient data-related regulations that contributed to laying a foundation for the sophistication of related products.
According to the U.S. market research firm MarketsandMarkets, the size of the nation’s AI healthcare market is forecast to grow by 45 percent per year, reaching about 2.44 trillion won in 2025.
J. S. Shin (js_shin@koreabizwire.com)
